Role of Toll-like Receptors and their Adaptors in Adjuvant Immunotherapy for Cancer

Anticancer Research

Volumn 23, Issue 6 A, 2003, Pages 4369-4376

  Seya, Tsukasa ^a,b,d   Akazawa, Takashi ^a   Uehori, Junji ^a,b   Matsumoto, Misako ^a   Azuma, Ichiro ^c   Toyoshima, Kumao ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c HAKODATE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^d Osaka Medical Center for Cancer and Cardiovascular   (Japan)

Author keywords

Adjuvants; BCG cell wall skeleton; Double stranded RNA; Innate immunity; Toll like receptor

Indexed keywords

ADAPTOR PROTEIN; BCG VACCINE; DOUBLE STRANDED RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN TICAM 1; PROTEIN TICAM 2; PROTEIN TIRAP; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CONFERENCE PAPER; CYTOSKELETON; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DISSECTION; DRUG MECHANISM; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INTERFERON PRODUCTION; LUNG CANCER; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIDE EFFECT; TUMOR CELL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTORS;

EID: 0344009684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.
2. Khong HT and Restifo NP: Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005, 2002.
3. Groopman JE: Neoplasms in the acquired immune deficiency syndrome: the multidisciplinary approach to treatment. Semin Oncol 14: 1-6, 1987.
4. Stutman O: Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst 62: 353-8, 1979.
5. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM and Ohashi PS: Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186: 645-53, 1997.
6. Lauritzsen GF, Weiss S, Dembic Z and Bogen B: Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91: 5700-4, 1994.
7. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-11, 2001.
8. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H and Zinkernagel RM: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-64, 2001.
9. Freund J: The mode of action of immunopharmacological adjuvants. Adv Tuberc Res 1: 130-48, 1956.
10. Anderson KV, Jurgens G and Nusslein-Volhard C: Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42: 779-89, 1985.
11. Lemaitre B, Nicolas E, Michaut L, Reichhart JM and Hoffmann JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973-981, 1996.
12. Medzhitov R, Preston-Hurlburt P and Janeway CA: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997.
13. Medzhitov R: Toll-like receptors and innate immunity. Nature Rev Immunol 1: 135-45, 2001.
14. Medzhitov R and Janeway Jr CA: Innate immunity: the virtues of a nonclonal system of recognition. Cell 91: 295-298, 1997.
15. Kadowaki M, Ho S, Antonenko S, de Waal Malefyt R, Kastelein RA, Bazan F and Liu YJ: Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863-870, 2001.
16. Akira S, Takeda K and Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-80, 2001.
17. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ and Knaus UG: Toll-like receptor 2-mediated NF-kappaB activation requires a Rac1-dependent pathway. Nat Immunol 1: 533-540, 2000.
18. Hazeki K, Masuda N, Funami K, Sukenobu N, Matsumoto M, Akira S, Takeda K, Seya T and Hazeki O: TLR-mediated tyrosine phosphorylation of paxillin via MyD88-dependent and -independent pathways. Eur J Immunol 33: 740-7, 2003.
19. Oshiumi H, Matsumoto M, Funami K, Akazawa T and Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon β-induction. Nat Immunol 4: 161-167, 2003.
20. Nishiguchi M, Matsumoto M, Takao T, Hoshino M, Shimonishi Y, Tsuji S, Begum NA, Takeuchi O, Akira S, Toyoshima K and Seya T: Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J Immunol 166: 2610-2616, 2001.
21. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L and Aderem A: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 97: 13766-71, 2000.
22. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K and Akira S: Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169: 6668-6672, 2002.
23. Oshiumi H, Shida K, Sasai M, Fujita T, Matsumoto M and Seya T: Identification of the Toll-like receptor (TLR)-adapter that participates in TLR4-mediated interferon-beta induction. J Biol Chem (in press), 2003.
24. Hardiman G, Rock FL, Balasubramanian S, Kastelein RA and Bazan JF: Molecular characterization and modular analysis of human MyD88. Oncogene 13: 2467-2475, 1996.
25. Schnare M, Barton GM, Holt AC, Takeda K, Akira S and Medzhitov R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2: 947-50, 2001.
26. Horng T, Barton GM and Medzhitov R: TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2: 835-841, 2001.
27. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA and O'Neill LA: Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413: 78-83, 2001.
28. Kawai T, Adachi O, Ogawa T, Takeda K and Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-22, 1999.
29. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K and Akira S: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420: 324-329, 2002.
30. Horng T, Barton GM, Flavell RA and Medzhitov R: The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420: 329-333, 2002.
31. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K and Seya T: Maturation of human human dendritic cells by cell-wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: involvement of Toll-like receptors. Infect Immun 68: 6883-90, 2000.
32. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K and Seya T: Simultaneous blocking of human Toll-like receptor 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin (BCG)-peptidoglycan (PGN). Infect Immun 71: 4238-4249, 2003.
33. Hayashi A, Doi O, Azuma I and Toyoshima K: Immunofriendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Jpn Acad 74: Ser. B 50-5, 1998.
34. Matsumoto M, Seya T, Kikkawa S, Tsuji S, Shida K, Nomura M, Kurita-Taniguchi M, Higashiyama M, Ohigashi H, Yokouchi H, Takami H, Hayashi A, Azuma I, Masaoka T, Kodama K and Toyoshima K: Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG-cell wall skeleton. Int Immunopharmacol 1: 1559-69, 2001.
35. Seya T, Matsumoto M, Tsuji S, Begum NA, Azuma I and Toyoshima K: Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG-cell wall skeleton and Mycoplasma lipoprotein M161Ag. Microbes Infect 4: 955-961, 2002.
36. Kaisho T and Akira S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589: 1-13, 2002.
37. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, Ahmed SU, Akashi S, Miyake K, Takeuchi O, Akira S, Moriya Y, Matsubara S, Ryoma Y, Saito M and Sato M: Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95: 316-26, 2003.
38. Fujiwara H and Hamaoka T: Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int Immunopharmacol 1: 613-23, 2001.
39. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M and Takahashi T: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32, 2001.
40. Kawai T, Adachi O, Ogawa T, Takeda K and Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122, 1999.
41. Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Akira S, Azuma I, Toyoshima K and Seya T: Adjuvant-mediated tumor regression and tumor-specific CTL induction are impaired in MyD88-deficient mice, Cancer Res (in press), 2003.
42. Kaisho T, Takeuchi O, Kawai T, Hoshino K and Akira S: Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 166: 5688-5694, 2001.
43. Sareneva T, Julkunen I and Matikainen S: IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol 165: 1933-8, 2000.
44. Pardoll D: T cell and tumours. Nature 411: 1010-1012, 2001.
45. Matsumoto M, Funamik K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A and Seya T: Subcellular localization of human Toll-like receptor 3 in human dendritic cells. J Immunol 171: 3154-3162, 2003.
46. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K and Taniguchi T: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature Jul 16 [Epub ahead of print] 2003.